DR. Frank J. Hsu M.D. serves as Chief Medical Officer of the Company. From October 2013 to October 2018, he served as Vice President and Head of Oncology at Immune Design Corporation prior to its acquisition by Merck Co., Inc., where he was responsible for development of several immuno-oncology programs and first-in-human studies and later stage studies in both hematologic malignancies and solid cancers. From June 2012 to June 2013, Dr. Hsu served as Chief Medical Officer at Zyngenia, Inc., where he was responsible for development of its multivalent antibody/protein therapeutics. Dr. Hsu started his biotech industry career as a Senior Medical Director at Genzyme Corporation from November 2002 to 2012, prior to its acquisition by Sanofi, S.A, and over a 10-year period led several multifunctional teams and oversaw the clinical development of multiple investigational and approved agents, including Mozobil®, Campath®, fresolimumab, and other immuno-oncology agents. Before joining the biotech industry, Dr. Hsu had a distinguished career in academics. He was a faculty member at Yale University from September 1996 through December 2002, serving as an Assistant Professor of Medicine in the Section of Oncology and co-Director/Director of the Immunology Research Program of the Yale Cancer Center, and was a clinical and research fellow with Dr. Ron Levy at Stanford from 1990 to 1996. Dr. Hsu’s basic and translational research was in the development of lymphoma vaccines and antibody therapeutics and included the first clinical trial of a dendritic cell-based vaccine. These clinical studies provided the rationale and basis for the development of Provenge®. Dr. Hsu holds a B.S. degree in biology from Stanford University, and an M.D. degree from Harvard Medical School and the Health Science and Technology Program at the Massachusetts Institute of Technology. He completed his internship/residency in Internal Medicine at the University of California, San Francisco and his oncology training at Stanford University.
As the Chief Medical Officer of Oncternal Therapeutics, the total compensation of Frank Hsu at Oncternal Therapeutics is 769,143$. There are 2 executives at Oncternal Therapeutics getting paid more, with James Breitmeyer having the highest compensation of 1,115,840$.
Frank Hsu is 59, he's been the Chief Medical Officer of Oncternal Therapeutics since 2019. There are 7 older and 8 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.
Frank's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 300, , SAN DIEGO, CA, 92130.
Over the last 5 years, insiders at Oncternal Therapeutics have traded over 26,287$ worth of Oncternal Therapeutics stock and bought 1,526,610 units worth 3,062,129$ . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh...、Charles Theuer、Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of 302,970$. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth 27,651$.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
Oncternal Therapeutics executives and other stock owners filed with the SEC include: